EVALUATION OF ANTIDYSLIPIDEMIC EFFECT OF MANGIFERIN AND AMAROGENTIN FROM SWERTIA CHIRAYITA EXTRACT IN HFD INDUCED CHARLES FOSTER RAT MODEL AND IN VITRO ANTIOXIDANT ACTIVITY AND THEIR DOCKING STUDIES

Swertia chirayita (SC) has been traditionally used for the treatment of several metabolic disorders related to health problems. We have investigated the antidyslipidemic and antioxidant potential of Swertia chirayita (SC) plant, a potent antidiabetic, and its isolated markers. The LC-ESI-MS standardized hot water extracts of different batches from the whole plant of Swertia chirayita, were tested in-vivo for their antidyslipidemic activity in Triton (WR-1339) and high-fat diet (HFD) induced dyslipidemic Charles Foster rats and in vitro for their antioxidant activity. Further solvent fractionation and isolation resulted in the identification of antidyslipidemic Mangiferin (MG) and Amarogentin (AM). Treatment of hyperlipidemic rats with MG and AM at 100 and 200mg/kg doses caused reduction in plasma levels of Low density lipoprotein (LDL) 24, 26% and very low – density lipoprotein (VLDL) 19, 25% as well as increase in levels of High density lipoprotein (HDL) 18, 22% respectively. In rats with HFD, MG and AM significantly reduced levels of VLDL lipids (26% and 27%) as well as Low-density lipoprotein-Total cholesterol (LDL-TC) 27% and 30% in hyperlipidemic rats at 100 and 200 mg/kg doses. This is the first report of AM demonstrated as an antidyslipidemic agent. MG and AM also showed inhibition of superoxide anion, hydroxyl free radicals and microsomal lipid peroxidation by 24 & 28%, 25 & 31% and 27 & 25%, respectively. Also, both MG and AM also demonstrated more effective inhibition at 5 μM and 10 μM of HMGR (HMG-CoA reductase) in comparison to Pravastatin, which was further confirmed by docking studies.